Detection of the Omicron BA.2.75 subvariant in Japan.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Evaluation of SARS-CoV-2 Variants After the Declaration of End of COVID-19 Pandemic: BA.2.86 (Pirola) and EG.5 (Eris) Variants as Global Public Health Concerns.Health science reports · 2025
   Article
2. The influence of Omicron on vaccine efficacy and durability: a neurology perspective.Clinical and experimental vaccine research · 2024
   Review
3. Omicron variant evolution on vaccines and monoclonal antibodies.Inflammopharmacology · 2023
   Review
4. Genomic evidence for reinfection with different Omicron subvariants.The Journal of infection · 2023
   Article
5. Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level?Annals of medicine and surgery (2012) · 2022
   Article
6. SARS-CoV-2: Searching for the Missing Variants.Viruses · 2022
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as